UK parliamentarians have again discussed how to get Vertex’s cystic Fibrosis drug Orkambi (ivacaftor/lumacaftor) to patients as talks between NHS England and the company stagger on with no conclusion. Seema Kennedy, the parliamentary under-secretary for health and social care, said the government would now start looking at all options on the table, including a compulsory license.
“The ideal thing is to get a deal, and deals have been done with other pharmaceutical companies,” Kennedy said. Echoing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?